Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 134

Sort by

Sort Order Select

Journal Articles

Combination of Nilotinib and Pegylated Interferon Alfa-2b Results in High Molecular Response Rates in Chronic Phase CML: Interim Results of the ALLG CML 11 Pinnacle Study

Blood (2018) 132 (Supplement 1): 459.

https://doi.org/10.1182/blood-2018-99-110569

Published: 2018

Journal Articles

Integration of Multiple Bioassays Using Machine Learning to Identify High-Risk CP-CML Patients Treated with Frontline Imatinib

Chung Hoow Kok, PhD BSc, Sakrapee Paisitkriangkrai, PhD, David T Yeung, PhD BSc, FRACP, FRCPA MBBS, Liu Liu, PhD BSc, Verity A Saunders, Phuong Dang, Agnes S. M. Yong, MD PhD, Deborah L White, PhD, Timothy P. Hughes, MD MBBS, FRACP, FRCPA

Blood (2018) 132 (Supplement 1): 1728.

https://doi.org/10.1182/blood-2018-99-117633

Published: 2018

Journal Articles

The e13a2 BCR-ABL1 Transcript Is Associated with Higher Rates of Molecular Recurrence after Treatment-Free Remission Attempts: Retrospective Analysis of the Adelaide Cohort

Naranie Shanmuganathan, MBBS, Susan Branford, PhD, Agnes S. M. Yong, MDPhD, Devendra K Hiwase, MBBS, MD FRACP, FRCPA, PhD, David T Yeung, PhDBSc,FRACP,FRCPA,MBBS, David M Ross, Timothy P. Hughes, MD

Blood (2018) 132 (Supplement 1): 1731.

https://doi.org/10.1182/blood-2018-99-111083

Published: 2018

Journal Articles

High Recombination Activating Gene (RAG) Expression and RAG Mediated Recombination Is Associated with Oncogenic Rearrangement Observed with Tyrosine Kinase Inhibitor Resistant CML

Daniel Thomson, PhD BSc, Hezrin Shahrin, PhD, Paul Wang, PhD, Carol Wadham, PhD, Timothy P. Hughes, MD MBBS, FRACP, FRCPA, Andreas Schreiber, PhD, Susan Branford, PhD

Blood (2018) 132 (Supplement 1): 3001.

https://doi.org/10.1182/blood-2018-99-111212

Published: 2018

Journal Articles

Arterial Occlusive Events (AOEs) in the Phase 2 Ponatinib PACE Trial: 5-Year Update in Heavily Treated Patients (Pts) with Chronic-Phase Chronic Myeloid Leukemia (CP-CML)

Blood (2017) 130 (Supplement 1): 2896.

https://doi.org/10.1182/blood.V130.Suppl_1.2896.2896

Published: 2017

Journal Articles

Nilotinib in Combination with Pegylated Interferon Alfa-2b for CP-CML Leads to High Molecular Response Rates: Interim Results of the Pinnacle Study

Blood (2017) 130 (Supplement 1): 2898.

https://doi.org/10.1182/blood.V130.Suppl_1.2898.2898

Published: 2017

Journal Articles

Treatment-Free Remission (TFR) Among Patients (pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Not Initially Eligible for Treatment Discontinuation Due to Unstable Deep Molecular Response (DMR): Enestfreedom and Enestop

Timothy P. Hughes, MD, Andreas Hochhaus, MD, Dong-Wook Kim, MD PhD, Francois-Xavier Mahon, MD PhD, Francis J. Giles, MD MB, FRCPath, Jerald P. Radich, MD, David M Ross, MBBS, PhD FRACP, FRCPA, Prashanth Gopalakrishna, MD, Weiping Deng, Rafik Fellague-Chebra, MD, Sandip Acharya, MSc, Giuseppe Saglio, MD PhD

Blood (2017) 130 (Supplement 1): 2878.

https://doi.org/10.1182/blood.V130.Suppl_1.2878.2878

Published: 2017

Journal Articles

Impact of Treatment Cessation on Overall Disease Outcomes in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Attempting Treatment-Free Remission (TFR): Findings from Enestfreedom and Enestop

Giuseppe Saglio, MD PhD, Timothy P. Hughes, MD, Andreas Hochhaus, MD, Dong-Wook Kim, MD PhD, Francis J. Giles, MD MB, FRCPath, Jerald P. Radich, MD, David M Ross, MBBS, PhD FRACP, FRCPA, Prashanth Gopalakrishna, MD, Weiping Deng, Rafik Fellague-Chebra, MD, Sandip Acharya, MSc, Francois-Xavier Mahon, MD PhD

Blood (2017) 130 (Supplement 1): 1598.

https://doi.org/10.1182/blood.V130.Suppl_1.1598.1598

Published: 2017

Journal Articles

Integrative Genomics Reveals Cancer Associated Mutations Are Common at Diagnosis of CML in Patients with Poor Response to TKI Therapy

Blood (2017) 130 (Supplement 1): 251.

https://doi.org/10.1182/blood.V130.Suppl_1.251.251

Published: 2017

Journal Articles

Efficacy and Safety of Ponatinib in Chronic Phase-Chronic Myeloid Leukemia (CP-CML) According to the Extent of Treatment with Prior Tyrosine Kinase Inhibitors (TKIs): Final (5-Year) Results of the PACE Study

Blood (2017) 130 (Supplement 1): 1617.

https://doi.org/10.1182/blood.V130.Suppl_1.1617.1617

Published: 2017

Journal Articles

Nilotinib/Interferon-α Combination Rapidly Enhances Leukaemia-Associated Antigen-Specific Cytotoxic T-Lymphocyte Immune Responses, Limits Natural Killer Cell Maturation and Triggers B Cell Remodelling

Amy Hughes, PhD, Jade Clarson, Deborah L White, PhD FFSc (RCPA), David Yeung, PhDBSc,FRACP,FRCPA,MBBS, Timothy P. Hughes, MD MBBS, FRACP, FRCPA, Agnes S. M. Yong, MDPhD

Blood (2017) 130 (Supplement 1): 1581.

https://doi.org/10.1182/blood.V130.Suppl_1.1581.1581

Published: 2017

Journal Articles

Cumulative Incidence of Treatment-Free Remission (TFR) for Patients with Chronic Myeloid Leukemia (CML): The Adelaide Experience

Naranie Shanmuganathan, MBBS, Susan Branford, PhD, David Yeung, PhDBSc,FRACP,FRCPA,MBBS, Devendra K Hiwase, MBBS, MD FRACP, FRCPA, PhD, Agnes S. M. Yong, MDPhD, David M Ross, MBBS, PhD FRACP, FRCPA, Timothy P. Hughes, MD MBBS, FRACP, FRCPA

Blood (2017) 130 (Supplement 1): 1621.

https://doi.org/10.1182/blood.V130.Suppl_1.1621.1621

Published: 2017

Journal Articles

Long-Term Follow-up of the ALLG CML8 Twister Study of Treatment-Free Remission (TFR) in Patients with Chronic Myeloid Leukemia (CML)

David M Ross, MBBS, PhD FRACP, FRCPA, Ilaria S Pagani, PhD, Naranie Shanmuganathan, MBBS, John F Seymour, MBBS, PhD, Anthony K Mills, FRACP, FRCPA, MBBS, Robin J Filshie, PhDFRACP,FRCPA, Christopher K Arthur, MDFRACP,FRCPA,MBBS, Phuong Dang, Verity A Saunders, Jody Braley, David T Yeung, PhDBSc,FRACP,FRCPA,MBBS, Deborah L White, PhD FFSc (RCPA), Andrew P Grigg, MBBS, MD FRACP, FRCPA, Anthony P Schwarer, MD MBBS (Hons), FRACP, FRCPA, Susan Branford, PhD, Timothy P. Hughes, MD

Blood (2017) 130 (Supplement 1): 1597.

https://doi.org/10.1182/blood.V130.Suppl_1.1597.1597

Published: 2017

Journal Articles

Enhanced Natural Killer and Cytotoxic T Lymphocyte Responses, with Decreased Monocytic Myeloid Derived Suppressor Cells May Promote Treatment Free Remission in Chronic Myeloid Leukaemia Patients Following Tyrosine Kinase Inhibitor Cessation

Amy Hughes, PhD, Jade Clarson, B.Sc, Deborah L White, PhD FFSc (RCPA), David M. Ross, MBBS, PhD FRACP, FRCPA, Timothy P. Hughes, MD FRACP, FRCPA, MBBS, FAAHMS, Agnes S Yong, MD PhD

Blood (2016) 128 (22): 1122.

https://doi.org/10.1182/blood.V128.22.1122.1122

Published: 2016

Journal Articles

Novel Fusion Genes at CML Diagnosis Reveal a Complex Pattern of Genomic Rearrangements and Sequence Inversions Associated with the Philadelphia Chromosome in Patients with Early Blast Crisis

Justine E Marum, PhD, Paul PS Wang, PhD, Doris Stangl, PhD, David T. Yeung, BSc, MBBS, FRACP, FRCPA, Martin C. Mueller, Christian T. Dietz, PhD, Ieuan Walker, MSc, BSc, MBBS, Nathalie Nataren, BSc, Zoe Donaldson, BSc, Wendy T Parker, PhD, David M. Ross, MBBS, PhD FRACP, FRCPA, Hamish S Scott, BSc, PhD FFSc (RCPA), FAHMS, Timothy P. Hughes, MD FRACP, FRCPA, MBBS, FAAHMS, Andreas W Schreiber, PhD, Susan Branford, PhD FFSc (RCPA)

Blood (2016) 128 (22): 1219.

https://doi.org/10.1182/blood.V128.22.1219.1219

Published: 2016

Journal Articles

A Low Concentration of ABL001 Potentiates In Vitro TKI-Induced Bcr-Abl Kinase Inhibition in CML Cells

Verity A Saunders, BSc (Hons), Jueqiong Wang, PhD, Liu Lu, PhD, Laura N Eadie, PhD, Jennifer A McLean, Jarrad M Goyne, BMedSc (Hons), David T. Yeung, BSc, MBBS, FRACP, FRCPA, Deborah L White, PhD FFSc (RCPA), Timothy P Hughes, MD FRACP, FRCPA, MBBS

Blood (2016) 128 (22): 1121.

https://doi.org/10.1182/blood.V128.22.1121.1121

Published: 2016

Journal Articles

Efficacy and Safety of Nilotinib 300 Mg Twice Daily (BD) in Patients with CML in Chronic Phase (CML-CP) Who Are Intolerant to Prior BCR-ABL Tyrosine Kinase Inhibitors (TKIs): Results from the Randomized, Phase IIIb E.N.E.S.Tswift Study

Devendra K Hiwase, MBBS, MD FRACP, FRCPA, PhD, Peter Tan, James D'Rozario, John Taper, MBBS FRACP FRCPA, Anthony Richard Powell, FRACP, MBBS, Ian Irving, Matthew P.F. Wright, MBBS, FRCPA, FRACP, Susan Branford, PhD FFSc (RCPA), David T. Yeung, BSc, MBBS, FRACP, FRCPA, Luke Anderson, Othon L Gervasio, Timothy P. Hughes, MD

Blood (2016) 128 (22): 5447.

https://doi.org/10.1182/blood.V128.22.5447.5447

Published: 2016

Journal Articles

Expanded Phase 1 Study of ABL001, a Potent, Allosteric Inhibitor of BCR-ABL, Reveals Significant and Durable Responses in Patients with CML-Chronic Phase with Failure of Prior TKI Therapy

Blood (2016) 128 (22): 625.

https://doi.org/10.1182/blood.V128.22.625.625

Published: 2016

Journal Articles

Upfront Imatinib with Selective Early Switching to Nilotinib Leads to Excellent Achievement of Deep Molecular Response in Chronic Phase CML: 5 Year (Final) Analysis of the TIDEL-II Study

Blood (2016) 128 (22): 939.

https://doi.org/10.1182/blood.V128.22.939.939

Published: 2016

Journal Articles

The ABCC6 Transporter Plays a Significant Role in the Efflux of Nilotinib and Dasatinib, and May Contribute to Tyrosine Kinase Inhibitor Resistance

Laura N Eadie, PhD, Jarrad M Goyne, BMedSc (Hons), Timothy P. Hughes, MD FRACP, FRCPA, MBBS, FAAHMS, Deborah L White, PhD FFSc (RCPA)

Blood (2016) 128 (22): 4237.

https://doi.org/10.1182/blood.V128.22.4237.4237

Published: 2016

NARROW

Combination of Nilotinib and Pegylated Interferon Alfa-2b Results in High Molecular Response Rates in Chronic Phase CML: Interim Results of the ALLG CML 11 Pinnacle Study

Integration of Multiple Bioassays Using Machine Learning to Identify High-Risk CP-CML Patients Treated with Frontline Imatinib

The e13a2 BCR-ABL1 Transcript Is Associated with Higher Rates of Molecular Recurrence after Treatment-Free Remission Attempts: Retrospective Analysis of the Adelaide Cohort

High Recombination Activating Gene (RAG) Expression and RAG Mediated Recombination Is Associated with Oncogenic Rearrangement Observed with Tyrosine Kinase Inhibitor Resistant CML

Arterial Occlusive Events (AOEs) in the Phase 2 Ponatinib PACE Trial: 5-Year Update in Heavily Treated Patients (Pts) with Chronic-Phase Chronic Myeloid Leukemia (CP-CML)

Nilotinib in Combination with Pegylated Interferon Alfa-2b for CP-CML Leads to High Molecular Response Rates: Interim Results of the Pinnacle Study

Treatment-Free Remission (TFR) Among Patients (pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Not Initially Eligible for Treatment Discontinuation Due to Unstable Deep Molecular Response (DMR): Enestfreedom and Enestop

Impact of Treatment Cessation on Overall Disease Outcomes in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Attempting Treatment-Free Remission (TFR): Findings from Enestfreedom and Enestop

Integrative Genomics Reveals Cancer Associated Mutations Are Common at Diagnosis of CML in Patients with Poor Response to TKI Therapy

Efficacy and Safety of Ponatinib in Chronic Phase-Chronic Myeloid Leukemia (CP-CML) According to the Extent of Treatment with Prior Tyrosine Kinase Inhibitors (TKIs): Final (5-Year) Results of the PACE Study

Nilotinib/Interferon-α Combination Rapidly Enhances Leukaemia-Associated Antigen-Specific Cytotoxic T-Lymphocyte Immune Responses, Limits Natural Killer Cell Maturation and Triggers B Cell Remodelling

Cumulative Incidence of Treatment-Free Remission (TFR) for Patients with Chronic Myeloid Leukemia (CML): The Adelaide Experience

Long-Term Follow-up of the ALLG CML8 Twister Study of Treatment-Free Remission (TFR) in Patients with Chronic Myeloid Leukemia (CML)

Enhanced Natural Killer and Cytotoxic T Lymphocyte Responses, with Decreased Monocytic Myeloid Derived Suppressor Cells May Promote Treatment Free Remission in Chronic Myeloid Leukaemia Patients Following Tyrosine Kinase Inhibitor Cessation

Novel Fusion Genes at CML Diagnosis Reveal a Complex Pattern of Genomic Rearrangements and Sequence Inversions Associated with the Philadelphia Chromosome in Patients with Early Blast Crisis

A Low Concentration of ABL001 Potentiates In Vitro TKI-Induced Bcr-Abl Kinase Inhibition in CML Cells

Efficacy and Safety of Nilotinib 300 Mg Twice Daily (BD) in Patients with CML in Chronic Phase (CML-CP) Who Are Intolerant to Prior BCR-ABL Tyrosine Kinase Inhibitors (TKIs): Results from the Randomized, Phase IIIb E.N.E.S.Tswift Study

Expanded Phase 1 Study of ABL001, a Potent, Allosteric Inhibitor of BCR-ABL, Reveals Significant and Durable Responses in Patients with CML-Chronic Phase with Failure of Prior TKI Therapy

Upfront Imatinib with Selective Early Switching to Nilotinib Leads to Excellent Achievement of Deep Molecular Response in Chronic Phase CML: 5 Year (Final) Analysis of the TIDEL-II Study

The ABCC6 Transporter Plays a Significant Role in the Efflux of Nilotinib and Dasatinib, and May Contribute to Tyrosine Kinase Inhibitor Resistance

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only